Emma Logan

420 total citations
11 papers, 75 citations indexed

About

Emma Logan is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Emma Logan has authored 11 papers receiving a total of 75 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 6 papers in Oncology and 4 papers in Immunology. Recurrent topics in Emma Logan's work include CAR-T cell therapy research (6 papers), Acute Myeloid Leukemia Research (3 papers) and Biosimilars and Bioanalytical Methods (2 papers). Emma Logan is often cited by papers focused on CAR-T cell therapy research (6 papers), Acute Myeloid Leukemia Research (3 papers) and Biosimilars and Bioanalytical Methods (2 papers). Emma Logan collaborates with scholars based in United States. Emma Logan's co-authors include Matthew J. Frigault, David Avigan, Jacalyn Rosenblatt, Angela Shen, Daniella Cook, Noopur Raje, Heather Daley, Michael R. Bishop, Sarah Nikiforow and Christopher R. Heery and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia Research.

In The Last Decade

Emma Logan

10 papers receiving 72 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emma Logan United States	4	62	37	25	21	15	11	75
Alice Piapi United Kingdom	5	49 0.8×	37 1.0×	18 0.7×	13 0.6×	28 1.9×	8	96
Reed Masakayan United States	2	76 1.2×	37 1.0×	19 0.8×	27 1.3×	23 1.5×	4	78
Meghan Menges United States	8	89 1.4×	50 1.4×	15 0.6×	21 1.0×	25 1.7×	16	106
Nitin Patel United States	4	44 0.7×	29 0.8×	27 1.1×	5 0.2×	10 0.7×	19	56
Pere Barba Spain	4	59 1.0×	13 0.4×	14 0.6×	10 0.5×	11 0.7×	17	67
Xugeng Wang China	4	107 1.7×	59 1.6×	64 2.6×	19 0.9×	46 3.1×	5	141
Siok Ping Yeo Singapore	4	42 0.7×	48 1.3×	13 0.5×	10 0.5×	28 1.9×	4	98
Harrison Silva United States	4	102 1.6×	33 0.9×	16 0.6×	34 1.6×	47 3.1×	7	122
Jeffrey Wolf United States	3	76 1.2×	34 0.9×	63 2.5×	6 0.3×	23 1.5×	3	98
Weihsu C. Chen Canada	3	58 0.9×	21 0.6×	18 0.7×	9 0.4×	57 3.8×	3	98

Countries citing papers authored by Emma Logan

Since Specialization

Citations

This map shows the geographic impact of Emma Logan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Logan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Logan more than expected).

Fields of papers citing papers by Emma Logan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emma Logan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Logan. The network helps show where Emma Logan may publish in the future.

Co-authorship network of co-authors of Emma Logan

This figure shows the co-authorship network connecting the top 25 collaborators of Emma Logan. A scholar is included among the top collaborators of Emma Logan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma Logan. Emma Logan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Aubrey, Brandon J., Traci M. Blonquist, Malgorzata McMasters, et al.. (2025). A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. Leukemia Research. 153. 107693–107693. 1 indexed citations

Liu, Yiwen, Kathleen Gallagher, Emma Logan, et al.. (2024). Trial-in-Progress: A Phase 2 Study of Ruxolitinib in Low-Risk Essential Thrombocythemia and Polycythemia Vera Patients with High Symptom Burden. Blood. 144(Supplement 1). 6644–6644.

Keudell, Gottfried von, Emma Logan, Robert Redd, et al.. (2024). A Phase 2 Trial Investigating Epcoritamab in Patients with Previously Treated Waldenstrom Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (WM-NET3). Blood. 144(Supplement 1). 6294–6294. 2 indexed citations

Frigault, Matthew J., Michael R. Bishop, Jacalyn Rosenblatt, et al.. (2022). Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Advances. 7(5). 768–777. 50 indexed citations

Bindal, Poorva, Caitlin A. Trottier, Laura E. Dodge, et al.. (2022). G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy. Blood. 140(Supplement 1). 5238–5240. 3 indexed citations

Frigault, Matthew J., Jacalyn Rosenblatt, Daniella Cook, et al.. (2022). Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma.. Journal of Clinical Oncology. 40(16_suppl). 8003–8003. 6 indexed citations

Trottier, Caitlin A., Christian P. Larsen, Poorva Bindal, et al.. (2021). 925. Infectious Complications Following Chimeric Antigen Receptor (CAR) T-cell Therapy. Open Forum Infectious Diseases. 8(Supplement_1). S554–S555. 1 indexed citations

Koshy, Anita G., Haesook T. Kim, Dina Stroopinsky, et al.. (2021). Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease. Blood. 138(Supplement 1). 264–264. 1 indexed citations

Frigault, Matthew J., Elizabeth O’Donnell, Noopur Raje, et al.. (2021). Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.. Journal of Clinical Oncology. 39(15_suppl). 8015–8015. 6 indexed citations

10.

Bhasin, Manoj, Germán Pihán, Dina Stroopinsky, et al.. (2019). Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine. Blood. 134(Supplement_1). 3832–3832. 1 indexed citations

11.

Fathi, Amir T., Traci M. Blonquist, Mark J. Levis, et al.. (2016). A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia. Blood. 128(22). 5218–5218. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact